Zoledronic Acid Oresund Pharma 5 mg/100 ml Norwe - Kinorwe - Statens legemiddelverk

zoledronic acid oresund pharma 5 mg/100 ml

oresund pharma aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg/100 ml

Colecalciferol EQL Pharma 2000 IE Norwe - Kinorwe - Statens legemiddelverk

colecalciferol eql pharma 2000 ie

eql pharma ab - kolekalsiferol - tablett - 2000 ie

Naltrexone POA Pharma 50 mg Norwe - Kinorwe - Statens legemiddelverk

naltrexone poa pharma 50 mg

poa pharma scandinavia ab - naltreksonhydroklorid - tablett, filmdrasjert - 50 mg

Melatonin Unimedic Pharma 1 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

melatonin unimedic pharma 1 mg/ ml

unimedic pharma ab - melatonin - mikstur, oppløsning - 1 mg/ ml

Pelmeg Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastim - nøytropeni - immunostimulants, - for å redusere varigheten av neutropenia og forekomsten av febrile neutropenia på grunn av kjemoterapi.

Flutiform K-haler 125 mikrog / 5 mikrog Norwe - Kinorwe - Statens legemiddelverk

flutiform k-haler 125 mikrog / 5 mikrog

mundipharma as - flutikasonpropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 125 mikrog / 5 mikrog

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for ytterligere informasjon, vennligst referer til seksjon 5.

Lamivudine Teva Pharma B.V. Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

lamivudine teva pharma b.v.

teva b.v.  - lamivudin - hiv-infeksjoner - antivirale midler til systemisk bruk - lamivudin teva pharma b. indikeres som en del av antiretroviral kombinationsbehandling for behandling av humane immunsviktvirus (hiv) -infiserte voksne og barn.

OxyNorm 10 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

oxynorm 10 mg/ ml

mundipharma as - oksykodonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 10 mg/ ml

OxyNorm 50 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

oxynorm 50 mg/ ml

mundipharma as - oksykodonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml